Canary Prostate Active Surveillance Study
This is a multi-center, prospective active surveillance study with selective intervention in
patients with previously untreated, clinically localized prostate cancer at diagnosis.
Candidates are assessed based on an extended core biopsy, serum PSA (including PSA kinetics,
if available), digital rectal examination (DRE), and assessment of cancer grade and extent.
Active surveillance is defined as serial PSA measurements and prostate examination with
routine prostate biopsy and therapeutic intervention considered at the time one or more of
- Grade or volume progression
- Clinical progression
The objectives of the study are as follows:
• To discover and confirm biomarkers that predict aggressive disease as defined by
pre-specified histological, PSA, clinical criteria, or outcomes based on these variables.
- To determine the proportion of patients on active surveillance who progress based on
the above criteria.
- To determine the clinical predictors of disease progression.
Observational Model: Cohort, Time Perspective: Prospective
Daniel W. Lin, MD
University of Washington
United States: Institutional Review Board
|University of Michigan||Ann Arbor, Michigan 48109-0624|
|Stanford University||Stanford, California 94305|
|Eastern Virginia Medical School||Norfolk, Virginia 23507|
|University of Washington||Seattle, Washington 98195|
|University of California, San Francisco||San Francisco, California 94143|
|Beth Israel Deaconess Medical Center/Harvard Medical School||Boston, Massachusetts 02115|
|University of Texas Health Science Center, San Antonio||San Antonio, Texas 78229|
|Veterans Affairs Puget Sound Health Care System||Seattle, Washington 98108|